Balantidiasis Market Research and Development Strategy 2019 by Leading Industry Players - Pfizer, Inc., Abbott, GlaxoSmithKline plc, Sanofi S.A., Novartis AG

A Broad Analysis of the "Worldwide Chondrosarcoma market “methodology of the leading organizations in the exactness of import/export utilization, market activity figures, cost, value, revenue and gross edges.

Market Synopsis of the Global Balantidiasis Market

Balantidiasis is a disease caused by the bacterium Balantidium coli which mainly affects the large intestine. The disease spreads through fecal-oral route due to the contamination of food and water by the feces of pig or human. Improper sanitary conditions and unsafe drinking water are important aspects for the spread of the diseases.

GET FREE SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/4725

The market is driven by the increasing prevalence of communicable diseases in rural areas for developing countries.

In addition, increasing research and development activities, technological advancements to identify the causes and risk factors for transmission of infectious agents and developing new solutions to minimize patient exposure is another major driver, fuelling the global market growth.

The global balantidiasis market is expected to grow at a CAGR of 2.1% during the forecast period.

Key Players in the Global Balantidiasis Market

Some of the key players in this market are Pfizer (U.S.)
Abbott (U.S.)
GlaxoSmithKline plc. (U.K)
BD (U.S.)
Sandoz International GmbH (Germany)
Amneal Pharmaceuticals LLC. (U.S.)
Akorn, Inc. (U.S.)
PharmaDerm, a division of Fougera Pharmaceuticals Inc. (U.S.).

Segments of the Global Balantidiasis Market

The global balantidiasis market is segmented on the basis of diagnosis, treatment, and end user.On the basis of diagnosis, the market is segmented into stool examination, sigmoidoscopy, biopsy, and others.

On the basis of treatment, the market is segmented into antibiotics, appendectomy, and others. Antibiotics segment is further divided into tetracycline, metronidazole, and others.On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Regional Analysis of the Global Balantidiasis Market

In Europe, the prevalence of balantidiasis is found to be low which is attributed to stringent regulations governing the manufacturing of food products and low prevalence of gastrointestinal diseases.

In Asia Pacific, the prevalence of balantidiasis is found increasing steadily as a result of increasing prevalence of colitis, chronic diarrhea, and, deep intestinal ulcerations, poor healthcare system, and availability of treatment options for various gastrointestinal diseases.

According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence of gastrointestinal diseases in Asia Pacific was 15.8 and mortality was 11.7 per 100,000. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.

BROWSE REPORT DETAILS AND IN-DEPTH TOC @ https://www.marketresearchfuture.com/reports/balantidiasis-market-4725

Some Points form Table of Content of Global Balantidiasis Market

Report Prologue
Market Introduction
2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Research Methodology
3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

..Continued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.